Cidara Therapeutics (CDTX) AI Stock Analysis

• Market Cap: $6.89B
• Dividend Yield: N/A
• Average Volume (3M): 1.62M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.46
• Revenue Growth: -100.00%
• EPS Growth: 53.89%
• Country: US
• Employees: 38
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.10
• Shares Outstanding: 31,439,371
• 10 Day Avg. Volume: 3,042,349
• 30 Day Avg. Volume: 1,619,486
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.05
• Price to Sales (P/S): 133.87
• P/FCF Ratio: -0.97
• Enterprise Value/Market Cap: 0.31
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -47.78
• Enterprise Value/Ebitda: -11.32
• 1Y Price Target: $209.67
• Price Target Upside: -4.27% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 8
• EPS Forecast (FY): -7.28
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $225.00 ▲(2.73% Upside)

Cidara Therapeutics' overall stock score is driven by strong technical momentum, despite significant financial challenges and valuation concerns. The earnings call provided positive guidance on CD388's development, but manufacturing and enrollment risks remain.

Positive Factors

Strategic Acquisition

The acquisition by Merck provides Cidara with significant resources and stability, enhancing its ability to develop and commercialize its therapies, potentially accelerating growth and innovation.

FDA Breakthrough Designation

This designation can expedite the development and review process, potentially bringing CD388 to market faster, addressing unmet medical needs and enhancing Cidara's competitive position.

Strong Financial Position

A robust cash position ensures that Cidara can fund its Phase III program and other strategic initiatives without immediate financial strain, supporting long-term operational stability.

Negative Factors

Persistent Financial Losses

Ongoing financial losses and dependency on external funding highlight operational inefficiencies and pose risks to long-term sustainability if not addressed.

Negative Revenue Growth

A significant decline in revenue indicates challenges in product commercialization and market penetration, potentially affecting future growth prospects.

Manufacturing Challenges

Manufacturing bottlenecks could delay regulatory filings and market entry, impacting the company's ability to capitalize on its R&D investments and competitive edge.

Cidara Therapeutics Business Overview & Revenue Model

Company Description

Cidara Therapeutics (CDTX) is a biotechnology company focused on the development of novel therapeutics for the treatment of fungal infections and other serious diseases. The company operates primarily in the biotechnology sector, leveraging its innovative platform to design and develop new medicines that address unmet medical needs. Cidara's core products include its lead candidate, rezafungin, an antifungal agent aimed at treating invasive fungal infections, and its Cloudbreak platform, which is designed for the development of combination therapies.

How the Company Makes Money

Cidara Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company likely makes money through milestone payments from partnerships with larger pharmaceutical companies, licensing agreements, and potential royalties from product sales once their therapies are approved and marketed. Significant partnerships with established pharmaceutical firms for co-development or distribution of its products can also contribute to revenue, along with government grants and funding aimed at supporting research and development efforts.

Cidara Therapeutics Financial Statement Overview

Summary

Cidara Therapeutics faces significant financial challenges with persistent losses and negative cash flows. The income statement reveals a drastic revenue decline and deeply negative profit margins. The balance sheet shows low leverage but historically negative equity, while cash flow is heavily reliant on external financing.

Income Statement

Cidara Therapeutics has experienced a significant revenue decline in the latest year, with a revenue growth rate of -98% from the previous year. The net profit margin is deeply negative, at -13362.04% for 2024, indicating substantial losses relative to revenue. The gross profit margin is also negative, suggesting that the company is selling below cost. While biotechnology companies often face high R&D expenses, the magnitude of losses is concerning.

Balance Sheet

The company's debt-to-equity ratio is low due to a relatively high stockholders' equity, indicating low leverage. However, the equity ratio is 76.02%, reflecting a stable capital structure. Despite this, the company has historically negative equity, raising concerns about sustainable financial health. The increase in cash reserves provides some liquidity cushion.

Cash Flow

Operating cash flow is significantly negative, although there has been substantial cash inflow from financing activities. Free cash flow remains negative, and the operating cash flow to net income ratio is negative, due to both operating cash flow and net income being negative. The company is heavily dependent on external financing to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	1.27M	23.28M	64.45M	49.57M	12.07M
Gross Profit	-45.00M	1.27M	-13.48M	64.45M	-23.52M	12.07M
EBITDA	-189.91M	-175.87M	-26.95M	-33.36M	-42.07M	-70.80M
Net Income	-184.74M	-169.83M	-22.93M	-33.58M	-42.47M	-72.11M
Balance Sheet
Total Assets	518.65M	214.80M	67.03M	47.49M	75.33M	60.42M
Cash, Cash Equivalents and Short-Term Investments	293.65M	189.82M	35.78M	32.73M	62.27M	35.91M
Total Debt	1.98M	3.58M	4.88M	1.21M	5.06M	7.96M
Total Liabilities	96.26M	51.49M	75.24M	61.92M	53.75M	49.71M
Stockholders Equity	422.39M	163.31M	-8.21M	-14.44M	21.57M	10.71M
Cash Flow
Free Cash Flow	-132.94M	-176.66M	-22.94M	-28.59M	-25.27M	-54.60M
Operating Cash Flow	-132.94M	-176.53M	-22.43M	-28.47M	-25.23M	-54.41M
Investing Cash Flow	-176.28M	-129.00K	-505.00K	-118.00K	-41.00K	-186.00K
Financing Cash Flow	481.83M	337.06M	25.98M	-951.00K	44.60M	37.28M

Cidara Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 219.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CDTX, the sentiment is Positive. The current price of 219.02 is above the 20-day moving average (MA) of 132.13, above the 50-day MA of 108.03, and above the 200-day MA of 54.02, indicating a bullish trend. The MACD of 30.36 indicates Negative momentum. The RSI at 88.88 is Negative, neither overbought nor oversold. The STOCH value of 99.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CDTX.

Cidara Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CPRX	83 Outperform	$2.77B	13.14	27.52%	―	25.56%	44.42%
ARQT	60 Neutral	$3.21B	―	-28.17%	―	129.21%	80.35%
TARS	60 Neutral	$3.27B	―	-28.35%	―	182.44%	47.21%
CDTX	57 Neutral	$6.89B	―	-68.70%	―	-100.00%	53.89%
IDYA	56 Neutral	$2.90B	―	-14.15%	―	5376.27%	20.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BEAM	40 Neutral	$2.13B	-4.64	-47.19%	―	-84.07%	-157.71%

Cidara Therapeutics Corporate Events

Cidara Therapeutics Enters Merger Agreement with Merck

On November 13, 2025, Cidara Therapeutics entered into a merger agreement with Merck, where Merck will acquire Cidara for $221.50 per share, totaling approximately $9.2 billion. This acquisition aims to diversify Merck’s portfolio by including Cidara’s investigational antiviral agent, CD388, which is currently in Phase 3 trials for preventing influenza in high-risk individuals. The merger is expected to close in the first quarter of 2026, pending regulatory approvals and other customary conditions. This strategic move aligns with Merck’s science-led business development strategy and is anticipated to enhance its pipeline, potentially driving growth and providing significant value to shareholders.

The most recent analyst rating on (CDTX) stock is a Hold with a $102.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.

Cidara Therapeutics’ Earnings Call Highlights CD388 Progress

Cidara Therapeutics Inc. recently held its earnings call, revealing a generally optimistic sentiment with significant advancements in the development and funding of its lead candidate, CD388. The company demonstrated strong financial positioning, although it acknowledged challenges related to manufacturing scale-up and uncertainties in flu vaccination rates and study enrollment timing.

Cidara Therapeutics Advances CD388 with Phase 3 Expansion

Cidara Therapeutics, Inc., a biotechnology company based in San Diego, is focused on developing drug-Fc conjugate therapeutics using its proprietary Cloudbreak platform, with a lead candidate aimed at preventing influenza.

Cidara Therapeutics’ CD388 Study: A Potential Game-Changer in Influenza Prevention

Study Overview: Cidara Therapeutics Inc. is conducting a Phase 3 study titled A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications. The study aims to assess the effectiveness of CD388 in preventing laboratory-confirmed influenza infections and its safety compared to a placebo.

Cidara Therapeutics Expands Phase 3 Trial for CD388

On September 24, 2025, Cidara Therapeutics announced an update to its Phase 3 trial plan for CD388 following discussions with the FDA. The trial will now include a broader population, potentially increasing eligible patients in the U.S. from 50 million to over 100 million, and will begin enrollment by the end of September 2025, six months earlier than initially planned.

The most recent analyst rating on (CDTX) stock is a Buy with a $123.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.